106 related articles for article (PubMed ID: 31428934)
1. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
[TBL] [Abstract][Full Text] [Related]
3. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
4. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract][Full Text] [Related]
6. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
Wang Q; Tang Z; Li C; Li X; Su C
Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
[TBL] [Abstract][Full Text] [Related]
7. Characterization of
Kim S; Kim J; Jung Y; Jun Y; Jung Y; Lee HY; Keum J; Park BJ; Lee J; Kim J; Lee S; Kim J
Mol Cells; 2020 Jul; 43(7):619-631. PubMed ID: 32638704
[TBL] [Abstract][Full Text] [Related]
8. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
9. UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma.
Kostyrko K; Román M; Lee AG; Simpson DR; Dinh PT; Leung SG; Marini KD; Kelly MR; Broyde J; Califano A; Jackson PK; Sweet-Cordero EA
Nat Commun; 2023 Jul; 14(1):3966. PubMed ID: 37407562
[TBL] [Abstract][Full Text] [Related]
10. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
[TBL] [Abstract][Full Text] [Related]
11. KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma.
Li N; Tian Y; Liu X; Pan C; Xue J
Medicine (Baltimore); 2023 Dec; 102(52):e36597. PubMed ID: 38206735
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
Mustachio LM; Lu Y; Tafe LJ; Memoli V; Rodriguez-Canales J; Mino B; Villalobos PA; Wistuba I; Katayama H; Hanash SM; Roszik J; Kawakami M; Cho KJ; Hancock JF; Chinyengetere F; Hu S; Liu X; Freemantle SJ; Dmitrovsky E
Mol Cancer Res; 2017 Jul; 15(7):905-914. PubMed ID: 28242811
[No Abstract] [Full Text] [Related]
13. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.
Iams WT; Beckermann KE; Almodovar K; Hernandez J; Vnencak-Jones C; Lim LP; Raymond CK; Horn L; Lovly CM
J Thorac Oncol; 2019 Mar; 14(3):e45-e48. PubMed ID: 30543839
[No Abstract] [Full Text] [Related]
14. Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin.
Phelps CA; Lindsey-Boltz L; Sancar A; Mu D
Sci Rep; 2019 May; 9(1):7990. PubMed ID: 31142791
[TBL] [Abstract][Full Text] [Related]
15. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081
[TBL] [Abstract][Full Text] [Related]
16. Transcription start site-level expression of thyroid transcription factor 1 isoforms in lung adenocarcinoma and its clinicopathological significance.
Sano K; Hayashi T; Suehara Y; Hosoya M; Takamochi K; Kohsaka S; Kishikawa S; Kishi M; Saito S; Takahashi F; Kaneko K; Suzuki K; Yao T; Ishijima M; Saito T
J Pathol Clin Res; 2021 Jul; 7(4):361-374. PubMed ID: 34014042
[TBL] [Abstract][Full Text] [Related]
17. HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma.
Li Y; Zhang X; Zhu S; Dejene EA; Peng W; Sepulveda A; Seto E
Cancer Res; 2020 Aug; 80(16):3265-3278. PubMed ID: 32540961
[TBL] [Abstract][Full Text] [Related]
18. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract][Full Text] [Related]
19. Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the Lung.
Li Y; Xi SY; Yong JJ; Wu XY; Yang XH; Wang F
Am J Surg Pathol; 2021 Nov; 45(11):1464-1475. PubMed ID: 34138800
[TBL] [Abstract][Full Text] [Related]
20. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]